Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- (-) Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- NPC News
- Pandemic Response
- (-) Patient Centered Formulary & Benefit Design
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Audience
Display Only
Showing 59 Results
Savvy Employers Alter Status Quo to Address Drugs, Deductibles and Disincentives for Treatment
Thanks to an IRS rule, high-deductible health plans with health savings accounts can now cover an expanded list of preventive services and drugs before patients meet their plan’s annual out-of-pocket…
Health Plan Enrollment May be Open, but Drug Coverage Is Still a Black Box for Many People
Most people choose coverage based mainly on the price – the health care premiums and deductibles. But a narrow focus on health care costs overlooks the overall quality of the health plan. Consumers…
Racial and Socioeconomic Disparities: Ignoring Inequitable Benefit Design Is Not an Option
In a new commentary published in BenefitsPro, Kimberly Westrich, NPC Vice President for Health Services Research, and Bruce Sherman, MD, medical advisor for the National Alliance of Healthcare…
Updated Tools Developed to Communicate High-Quality Information About New Treatments and Inform Health Plan Coverage and Reimbursement
NPC said that with the release of the new AMCP Format for Formulary Submissions, biopharmaceutical manufacturers and health plans will have a practical guide to exchange clinical and economic…
Principles for Sound Pharmacy and Therapeutics Practices: What’s Next
AMCP's Partnership Forum, “Principles for Sound Pharmacy and Therapeutics (P&T) Practices: What’s Next?” focused on the current state of P&T committees, challenges faced by these committees…
How Can We Elevate the Patient Voice in Value-Based Payment for Oncology?
A new study from the National Pharmaceutical Council (NPC) and Discern Health sheds new light on progress in making value-based reimbursement mechanisms, like accountable care, patient-centered.
Case Study Shows Benefits of Engaging Employees in Health Benefit Design
As open enrollment season for health insurance gets underway, a new case study shows that employees who are meaningfully engaged in deliberating and designing their health care benefits may have a…
NPC in Specialty Pharmacy Times: Inconsistent Specialty Pharmaceutical Coverage Threatens Care Coordination, Continuity
In his latest column for Specialty Pharmacy Times, NPC President and Chief Executive Officer Dan Leonard explores research published in Health Affairs that sheds light on when and how payers cover…
Managing PBMs: An Employer’s Perspective
During a webinar hosted by the Integrated Benefits Institute on March 5, Chuck Reynolds, consultant for Benfield, a Division of Gallagher Benefit Services, and Kristen Putnam, Director, Global…
Coverage Decisions May Drive Potential Health Care System Inefficiency
New research from Tufts Medical Center and the National Pharmaceutical Council indicates that patient access to therapies depends on factors other than cost and clinical benefit.
NPC Talks Value, Benefit Design at AMCP Research Symposium and Nexus 2017
The National Pharmaceutical Council (NPC) is pleased to be participating in next week’s Academy of Managed Care Pharmacy (AMCP) Nexus 2017 meeting in Dallas, Texas. As a sponsor of and participant in…
NPC in Chain Drug Review: Should Patients With the Same Condition Bear Different Costs?
NPC President Dan Leonard tackles variable copays in his latest commentary for Chain Drug Review. In it, he considers when variable cost-sharing is less acceptable for patients who require higher…
Same Condition, Different Costs: Should Patients Pay Different Amounts?
Patients who have the same condition sometimes pay different out-of-pocket costs for their medications, but when is this differential more appropriate? Join NPC in tackling this dilemma in the…
Learn More About Oncology Clinical Pathways in Webinar from Turning the Tide Against Cancer
Ideally, clinical pathways can be a useful tool to help clinicians make sense of quickly evolving science, ensure patients receive the right care at the right time, help standardize care and limit…
Incorporating What Matters to Patients in Quality Measures: A Discussion With NPAF’s Dr. Balch
NPC spoke with Alan Balch, PhD, chief executive officer of the National Patient Advocate Foundation, to ask his thoughts about the impact of quality measures on patient care, particularly in the…
When Is It Less Acceptable for Patients to Face Higher Cost-Sharing?
A new study explores when variation in consumer cost-sharing makes sense, and when it is less acceptable for patients with the same or similar conditions to have different out-of-pocket costs, as…
Pharmacy Benefits: Super-sized, Minimized or Right-Sized?
In the December issue of Employee Benefit News, NPC Vice President of Comparative Effectiveness Research Jennifer Graff, PharmD, outlines a framework for the consideration of treatment flexibility in…
Little Consistency in Evidence Cited by Commercial Health Plans for Specialty Drug Coverage
Evidence cited by payers in coverage decisions for specialty medicines varies significantly, with health plans only citing the same study in 15% of health plan coverage policies for a given drug and…
U.S. Care Pathways: Continued Focus on Oncology and Outstanding Challenges
A peer-reviewed study assessed changes in development, implementation, and evaluation of care pathways, and reviewed the latest evidence on integration of pathways with value-based care initiatives…